NN Group N.V. (LON:0QVV)

Verve Therapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	1,583	1,172	1,634	3,278	1,904
Depreciation & Amortization	120	117	110	117	118
Other Amortization	37	35	36	33	39
Gain (Loss) on Sale of Investments	-4,049	-3,829	6,175	-1,667	-654
Change in Other Net Operating Assets	-539	37	-8,894	-4,050	5,166
Other Operating Activities	2,447	2,530	-7,180	-689	485
Operating Cash Flow	-401	62	-8,119	-2,594	7,004
Operating Cash Flow Growth	-	-	-	-	77.72%
Capital Expenditures	-	-	-	-47	-51
Sale of Property, Plant & Equipment	-	-	-	8	2
Cash Acquisitions	-3	-18	-547	-314	-539
Investment in Securities	2,476	4,694	6,487	1,925	3,479
Other Investing Activities	-	-	-	-171	235
Investing Cash Flow	2,565	4,533	6,012	-1,826	550
Long-Term Debt Issued	8,063	10,588	10,584	2,348	5,144
Total Debt Repaid	-10,168	-12,438	-6,816	-2,021	-5,549
Net Debt Issued (Repaid)	-2,105	-1,850	3,768	327	-405
Repurchases of Common Stock	-529	-632	-1,391	-545	-621
Common Dividends Paid	-764	-498	-491	-490	-472
Other Financing Activities	-13	-6	-122	-33	-6
Financing Cash Flow	-3,411	-2,986	1,764	-741	-1,504
Foreign Exchange Rate Adjustments	-31	-72	-142	-74	-
Net Cash Flow	-1,278	1,537	-485	-5,235	6,050
Free Cash Flow	-401	62	-8,119	-2,641	6,953
Free Cash Flow Growth	-	-	-	-	83.12%
Free Cash Flow Margin	-3.18%	0.47%	-95.43%	-13.84%	37.10%
Free Cash Flow Per Share	-1.48	0.22	-27.46	-8.54	22.10
Cash Interest Paid	1,352	762	569	634	574
Cash Income Tax Paid	304	270	145	397	250
Levered Free Cash Flow	-4,788	-12,759	-52,385	4,298	2,881
Unlevered Free Cash Flow	-2,787	-10,969	-52,385	4,623	3,201
Change in Net Working Capital	5,731	13,895	52,990	-2,378	-1,132

Source: S&P Global Market Intelligence. Insurance template. Financial Sources.